1. . Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993;43:655–661.
2. , , , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285–294.
3. . Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–1504.
4. , , , et al. The interferons: Biological effects mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7–15.
5. , , , et al. Interferon beta in the treatment of multiple sclerosis. Mechanism of action. Neurology 1998;51:682–689.
6. . Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491–1497.
7. . Randomized controlled trial of recombinant interferon beta-1a in secondary progressive MS. Clinical results. Neurology 2001;56:1496–1504.
8. . Interferon beta-1b in secondary progressive MS: Clinical and MRI results of a 3-year randomized controlled trial [Abstract]. Late Breaking News. Presented at the 52nd annual meeting of the American Academy of Neurology, San Diego, 2000.
9. , , , et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679–687.
10. , . Benign MS: A distinct clinical entity with therapeutic implications. In: Advances in Multiple Sclerosis, ed. . Heidelberg: Springer-Verlag, 2008. (Current Topics in Microbiology and Immunology, vol. 318); pp. 1–18.
11. , . Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 2006;67:511–513.
12. , , , et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr 2001;139:443–446.
13. , , , et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006;66:472–476.
14. , , . [The use of beta-interferon-1b in children and adolescents with multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova 2006;106:29–33.
15. , , , et al. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology, 2005. 64(5): pp. 888–90.
16. , , , et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics, 2001. 32(4): pp. 211–3.
17. , , , et al. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: Long-term results. Neurol Sci 2007;28:127–132.
18. , , , et al. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: A comparative cohort study. Eur J Paediatr Neurol 2008;12:205–209.
19. . Does benign multiple sclerosis today imply benign multiple sclerosis tomorrow? Implications for treatment. Neurology 2007;68:480–481.
20. , . Benign course in multiple sclerosis: A review. Acta Neurol Scand 2006;113:359–369.
21. , , , et al. Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Ann Neurol 2004;56:303–306.
22. , , , et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004;62:2031–2037.
23. , , , et al. The clinical impact of interferon beta antibodies in relapsing–remitting MS. J Neurol 2004;251:305–309.
24. , , . European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging – Measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290–297.
25. , , , et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976–1983.
26. . Immunomodulatory treatment of early onset multiple sclerosis: Results of an Italian Co-operative Study. Neurol Sci 2005;26(Suppl 4):S183–186.
27. , , , et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: Results of an Italian co-operative study. Mult Scler 2005;11:420–424.
28. , , , et al. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 2003;34:120–126.
29. , , , et al. Breakthrough disease in pediatric MS patients: a pediatric network experience. In Annual Meeting of the American Academy of Neurology. 2009: Seattle, WA.
30. , , , et al. Identifying and treating patients with suboptimal responses. Neurology 2004;63(Suppl 6):S33–40.
31. , , , et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009;66:54–59.
32. , , , et al. The prognostic value of initial relapses on the evolution of disability in patients with relapsing–remitting multiple sclerosis. Neuroepidemiology 2006;27:45–54.
33. , , , et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS; The EVIDENCE Trial. Neurology 2002;359:1453–1460.
34. , , , et al. Every other day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis; results of a 2-year prospective randomized multicenter study (INCOMIN). Lancet 2002;359:1453–1460.
35. . Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first 3 years. Neurology 1996;47:889–894.
36. , , , et al. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing remitting multiple sclerosis. Lancet 2003;302:1184–1191.
37. , , , et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina. Eur J Neurol 2008;15:386–393.
38. , , , et al. Switching first-line disease-modifying therapy after failure: Impact on the course of relapsing–remitting multiple sclerosis. Mult Scler 2009;15:50–58.